Saad Eltaib, Babkir Akram, Awadelkarim Abdalaziz M, Qureshi Faisal
Internal Medicine, AMITA Saint Francis Hospital, Evanston, USA.
Internal Medicine, Wayne State University Detroit Medical Center, Detroit, USA.
Cureus. 2022 Jul 18;14(7):e26993. doi: 10.7759/cureus.26993. eCollection 2022 Jul.
We present a novel case of severe hyperosmolar hyperglycemic derangement in an elderly patient - without a known history of diabetes mellitus - after the first injection of leuprolide for the treatment of metastatic prostate adenocarcinoma. Whilst the available literature provided accumulative evidence of an association between insulin resistance and the use of gonadotropin-releasing hormone (GnRH) agonists, the initial presentation of leuprolide-induced impaired glycemic tolerance with a hyperosmolar hyperglycemic state (HHS) represents a clinical rarity that was seldom reported. A literature review was conducted to explore the underlying mechanisms of leuprolide-associated glucose intolerance. Screening for diabetes is recommended for patients receiving leuprolide therapy to identify at-risk patients and close glycemic monitoring is warranted in diabetic patients to minimize serious complications from poor glycemic control induced by leuprolide.
我们报告了一例老年患者在首次注射亮丙瑞林治疗转移性前列腺腺癌后出现严重高渗性高血糖紊乱的新病例,该患者既往无糖尿病病史。虽然现有文献提供了胰岛素抵抗与使用促性腺激素释放激素(GnRH)激动剂之间存在关联的累积证据,但亮丙瑞林诱导的糖耐量受损伴高渗性高血糖状态(HHS)的初始表现是一种临床罕见情况,很少有报道。我们进行了文献综述以探讨亮丙瑞林相关葡萄糖不耐受的潜在机制。建议对接受亮丙瑞林治疗的患者进行糖尿病筛查,以识别高危患者,对于糖尿病患者,有必要进行密切的血糖监测,以尽量减少亮丙瑞林引起的血糖控制不佳导致的严重并发症。